NASDAQ:STIMNeuronetics Stock Price, Forecast & News

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STIM shares have increased by 45.4% and is now trading at $3.01.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neuronetics.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Neuronetics.

Neuronetics will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.13. The business earned $11.48 million during the quarter. Neuronetics had a negative net margin of 55.58% and a negative return on equity of 68.77%.
View Neuronetics' earnings history.

4 Wall Street analysts have issued 12-month price targets for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' stock price to reach $5.33 in the next year. This suggests a possible upside of 77.2% from the stock's current price.
View analysts' price targets for Neuronetics.

Media coverage about STIM stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neuronetics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about Neuronetics.

Neuronetics saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 269,900 shares, a drop of 18.2% from the June 30th total of 329,900 shares. Based on an average trading volume of 968,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 2.7% of the shares of the company are short sold.
View Neuronetics' Current Options Chain.

Some companies that are related to Neuronetics include iCAD (ICAD), Westaim (WEDXF), T2 Biosystems (TTOO), Lyra Therapeutics (LYRA), Apyx Medical (APYX), Liquidia Technologies (LQDA), TELA Bio (TELA), Restoration Robotics (HAIR), Soliton (SOLY), BeyondAirInc . (XAIR), Venus Concept (VERO), PAVmed (PAVM), Spectral Medical (EDTXF), Nephros (NEPH) and SANUWAVE Health (SNWV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Nokia Oyj (NOK), Novavax (NVAX) and Onconova Therapeutics (ONTX).

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $3.01.

Neuronetics has a market capitalization of $56.37 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]